Trial results show significant faster time to clinical improvement with Favipiravir: Glenmark

Results from the Phase 3 trial showed numerical improvements for the primary efficacy endpoint with 28.6 per cent faster viral clearance in the overall population in the Favipiravir plus standard supportive care compared to those in the standard supportive care alone (control arm) , Glenmark said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3eQ9vfM
via IFTTT